Yasmine Belkaid, PhD, Renuka Nayak, MD, PhD, and Jose U. Scher, MD, discussed a growing body of research designed to harness the microbiota communities that live on our exposed surfaces, from the gut to the skin and eyes.
Dan Kastner, MD, PhD, described the unique, genotype-first strategy that researchers used to identify and define VEXAS syndrome, a complex rheumatic disease that had not been defined by conventional research approaches.
In Sunday’s Oscar S. Gluck, MD Memorial Lecture, Marc Hochberg, MD, MPH, described research into the pathogenesis and progression of OA that has helped identify new targets for therapeutic intervention.
Musculoskeletal conditions, particularly rheumatic diseases like RA and lupus, are among the most common causes of employment problems, according to Edward H. Yelin, PhD, who delivered Sunday’s ARP Distinguished Lecture.
The FDA has been busy during the COVID-19 pandemic, with emergency use authorizations for two rheumatology agents, approvals for new agents, and new indications and safety warnings for both prescription and OTC medications.
During a Monday session, Amanda Crawford, CRNP, CCD, and Saba Mohiuddin, PharmD, BCACP, discussed the management of osteoporosis, with a special focus on diagnostic imaging and pharmaceutical interventions.